Cardiovascular Co-Morbidity and the Outcome after Myeloablative Hematopoietic Stem Cell Transplantat
Hematopoietic Stem Cell Transplantation for Lymphoma
Cardiovascular associated factors were reviewed and correlated to outcome after HCT. The mean follow-up period was 1074.8 ± 739.2 days. The Overall Survival (OS) rate was 68.3% and the 3-month survival rate was 89.1%. Multivariate analysis revealed that the independent risk factors for OS were High Sensitivity C-Reactive Protein (HsCRP), Abnormal Regional Wall Motion (ARWM), age, and Eastern Cooperative Oncology Group (ECOG) performance status.